Drug class
Topical nitric oxide (NO)-releasing agent; dermatologic anti-molluscum preparation
Mechanism of action
Berdazimer releases nitric oxide locally. The US prescribing information states that the mechanism of action for treatment of molluscum contagiosum is unknown; no more specific antiviral or immunological pathway should be asserted as established.
General use cases
- Topical treatment of molluscum contagiosum in adults and paediatric patients aged 1 year and older under the US FDA ZELSUVMI indication; apply to lesions only according to product instructions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
